Richmond, VA, United States of America

Robert Louis Duncan, Jr


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 1976-1979

Loading Chart...
4 patents (USPTO):Explore Patents

Title: *Innovations of Robert Louis Duncan, Jr.: A Contribution to Hypotensive Compounds*

Introduction

Robert Louis Duncan, Jr., an inventive mind based in Richmond, VA, has made significant strides in the field of pharmaceutical chemistry. With a total of four patents to his name, Duncan has focused particularly on the development of compounds with hypotensive properties. His innovative work reflects both his dedication to scientific research and his pursuit of new therapeutic solutions.

Latest Patents

Among Duncan's latest patents, the most notable include the "1-Substituted-3-aminoethoxypyrrolidines and use thereof." This invention outlines various derivatives of 3-aminoethoxypyrrolidines, emphasizing their hypotensive properties. The disclosed compounds possess a unique formula where R can be substituted with various aromatic and aliphatic groups, enhancing their pharmacological efficacy. These innovations showcase Duncan's commitment to advancing treatments for hypertension and related conditions.

Career Highlights

Robert Louis Duncan, Jr. is associated with A. H. Robins Company, Incorporated, where he has contributed significantly to the research and development of cardiovascular drugs. His work has not only expanded scientific knowledge but has also paved the way for future innovations in the pharmaceutical industry.

Collaborations

Throughout his career, Duncan has collaborated with esteemed colleagues, including Robert Frederick Boswell, Jr. and Robert F. Boswell. These collaborations illustrate the synergy achieved when talented individuals work together towards a common scientific goal, further enhancing the quality and impact of their research.

Conclusion

In summary, Robert Louis Duncan, Jr. continues to be a noteworthy figure in the realm of pharmaceutical innovations. His patents, especially in the area of hypotensive compounds, represent significant advancements that may contribute to improved therapeutic options for patients suffering from hypertension. As Duncan’s career progresses, he remains a pivotal contributor to the field of medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…